Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial

Objective. Until recently, advanced medullary thyroid cancer (MTC) had few treatment options except surgery. The mTOR inhibitor everolimus has shown encouraging results in neuroendocrine tumors. As part of a prospective phase II study, we analyzed the safety and efficacy of everolimus in advanced MT...

詳細記述

保存先:
書誌詳細
出版年:Int J Endocrinol
主要な著者: Schneider, T. C., de Wit, D., Links, T. P., van Erp, N. P., van der Hoeven, J. J. M., Gelderblom, H., van Wezel, T., van Eijk, R., Morreau, H., Guchelaar, H. J., Kapiteijn, E.
フォーマット: Artigo
言語:Inglês
出版事項: Hindawi Publishing Corporation 2015
主題:
Clinical Study
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4532868/
https://ncbi.nlm.nih.gov/pubmed/26294908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/348124
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料